Company
CSL Limited
Headquarters: Parkville, VIC, Australia
Founded: 1916
Employees: 25,000
CEO: Mr. Paul R. Perreault B.A.
Market Cap
A$143.77 Billion
AUD as of July 1, 2024
US$95.75 Billion
CSL Limited Categories
Australia Healthcare BiotechnologyAustralia Healthcare Australia Biotechnology
Company Description
CSL Limited is a biotechnology company providing products to treat and prevent serious human medical conditions. CSL is involved in the research, development, manufacturing, and marketing of a wide range of products including blood plasma derivatives, vaccines, antivenom, and cell culture reagents for medical and genetic research and manufacturing applications.
Top Competitors by Market Capitalization
Industry: Biotechnology
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | A$21.45 B |
| EBITDA | A$3.90 B |
| Gross Profit TTM | A$6.71 B |
| Profit Margin | 17.43% |
| Operating Margin | 32.45% |
| Quarterly Revenue Growth | 12.10% |
Stocks & Indices
CSL Limited has the following listings and related stock indices.
Stock: ASX: CSL wb_incandescent
Stock: FSX: CSJ wb_incandescent
Product & Services
blood plasma, vaccines, antivenom, other laboratory and medical products
Key People
Paul Perreault (CEO)